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The human norovirus (NoV) polyprotein is cleaved into mature non-structural proteins by both mature
NoV protease (Pro, NS6) and its un-cleaved precursor (ProPol, NS6-7). Processing order is well-
established with ‘early’ and ‘late’ cleavages, but the governing enzymatic mechanisms are unknown.
Enzyme kinetics of a GII Pro and ProPol were analyzed using synthetic peptides representing the ﬁve
natural polyprotein cleavage sites. The relative efﬁciency of cleavage of the individual peptides was
consistent with established polyprotein processing order, and primarily correlated with enzyme turnover
(kcat). Enzymatic efﬁciencies (kcat/Km) of ProPol at all ﬁve sites were equivalent to, or greater than, that of
Pro. Binding afﬁnities (Km) for the two least efﬁciently cleaved sites (p20/VPg, VPg/Pro) were 2–4-fold
higher than the other sites. This work further deﬁnes the role of ProPol in NoV polyprotein cleavage, and
demonstrates that human norovirus polyprotein processing order is primarily an inherent property of
enzymatic activity.
& 2013 Published by Elsevier Inc.Introduction
Noroviruses (NoV) are important human pathogens and a
major public health threat. They are a group of related non-
enveloped, single-stranded, positive sense RNA viruses that cause
acute gastroenteritis in humans. Noroviruses are responsible for 21
million infections and over 70,000 hospitalizations annually in the
USA, and account for 10–15% of severe cases of gastroenteritis in
children less than 5 years old (Hall et al., 2011). In the USA,
noroviruses are the most frequent cause of hospital-acquired
infections and are responsible for 65% of hospital unit closures
(Rhinehart et al., 2012). Genogroup II noroviruses have been the
major cause of gastroenteritis outbreaks in the USA since 2001
(Siebenga et al., 2009; Hall et al., 2011). Noroviruses have been
shown to remain infectious in groundwater for at least 61 days
(Seitz et al., 2011), a signiﬁcant issue, especially in developing
countries where NoV are estimated to cause 218,000 deaths
among children each year and 1.1 million hospitalizations (Patel
et al., 2008).
A member of the Caliciviridae family, the Norovirus genus consists
of ﬁve genogroups (GI–GV), while only GI, GII, and GIV infect humans.
Noroviruses have a 7.7 kb positive sense, single-stranded RNA gen-
ome that encodes three open reading frames (ORFs) (Jiang et al., 1993;lsevier Inc.
nd Immunology, Georgetown
W., Med-Dent Building, RM
1800.
a).Lambden et al., 1993; Kapikian, et al., 1997). The nonstructural
proteins are encoded in ORF1 (Fig. 5) and translated as a 200 kDa
polyprotein that is self-cleaved by the viral 3C-like protease (Pro, NS6)
(Hardy et al., 2002; Blakeney et al., 2003; Belliot et al., 2003). The
protease–polymerase precursor protein (ProPol, NS6-7), a stable
intracellular viral protein with both protease and polymerase activ-
ities, has been shown to partially process the ORF1 polyprotein
(Sosnovtseva et al., 1999; Wei et al., 2001; Belliot et al., 2003, 2005;
Schefﬂer et al., 2007). The human NoV ORF1 polypeptide processing
order has been established with two sites being cleaved ‘early’ and
three additional ‘late’ sites cleaved subsequently (Hardy et al., 2002;
Blakeney et al., 2003; Belliot et al., 2003) However, the underlying
enzymatic mechanisms controlling this process have not yet been
identiﬁed.
In this report, we have characterized a human NoV ProPol with
regard to pH, buffer conditions, and the presence of cations, and
provide the ﬁrst measurements of its enzyme kinetics using a
previously described assay (Viswanathan et al., 2013). Using
synthetic FRET peptides representing the ﬁve NoV ORF1 polypro-
tein cleavage sites, we determined kinetic values (Km and kcat) for a
human GII NoV Pro and ProPol to deﬁne the enzymatic parameters
that govern ORF1 polyprotein processing, and provide a mechan-
istic explanation for the observed processing order of norovirus
ORF1. Our studies demonstrate that the two ‘early’ sites exhibit a
much higher rate of protease reaction turnover (kcat) compared to
the three ‘late’ sites. The two least efﬁcient ‘late’ sites have the
lowest enzyme turnover coupled with Km values that are higher
than the other three cleavage sites.
Fig. 1. SDS-PAGE analysis of recombinant NoV Pro and ProPol. Proteins were
electrophoresed in a 4–12% bis–tris NuPAGEs polyacrylamide gel (Life Technologies) and
stained with Coomassie Blue dye. Lane M, molecular weight marker. Lane 1, puriﬁed
His–Pro (20.2 kDa). Lane 2, puriﬁed His–ProPol (77.0 kDa).
Fig. 2. NoV Pro and ProPol have similar activities in standard assay. Protease
assays were conducted in standard assay buffer using standard assay peptide
(EPDFHLQGPEDLAK) as described in the Experimental procedures section. Panel A.
Activity of Pro and ProPol. NoV Pro and ProPol concentrations were 0.5 mM and
substrate was held at 100-fold excess for all conditions. Data are presented (in
triplicate at each point) as mean RFU adjusted for background. Panel B. Comparison
of Pro and ProPol kinetics. Reaction velocity (means of two independent experi-
ments performed in triplicate) was plotted over a range of substrate concentration
(3.9–125 mM, using 1.0 mM enzyme).
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NoV Pro and ProPol share similar pH proﬁle and cation sensitivities
Buffer and assay conditions for human NoV Pro have been
previously optimized for enzymatic assays (Chang et al., 2012;
Viswanathan et al., 2013), but no studies have characterized NoV
ProPol with respect to similar parameters to optimize protease
activity. The activity of GII NoV ProPol was examined over a rangeof pH and the presence of various cations, and enzyme kinetics
were determined using a standard assay peptide (Table 1) (Zeitler
et al., 2006; Viswanathan et al., 2013). The ProPol construct used
for these studies contained an E181A change at the internal
protease cleavage site of ProPol which has been demonstrated to
prevent its own self-cleavage upon puriﬁcation and under assay
conditions, while still retaining enzymatic activity (Sosnovtseva
et al., 1999; Belliot et al., 2003; Wei et al., 2001; Schefﬂer et al.,
2007).
After 90 min of incubation, Pro and ProPol had comparable
overall activities (Fig. 2A). The kinetic parameters (kcat and Km) of
NoV Pro and ProPol with the standard assay peptide (Table 2,
Fig. 2B) were not signiﬁcantly different (p40.05, unpaired t test).
Overall, Pro and ProPol exhibited similar proﬁles with respect
to different assay components and conditions. NoV ProPol exhib-
ited an optimum pH ranging from 8.6–9.0, and followed the same
trend of higher activity with increasing pH as observed for Pro
(Fig. 3A). However, ProPol retained more activity at lower pH
compared to NoV Pro (64% vs. 34% at pH6.8) (Fig. 3A). Both
enzymes exhibited similar inhibition proﬁles in the presence of
NaCl, KCl (Fig. 3B), MgCl2, and MnCl2 (Fig. 3C). NoV Pro appeared to
be less sensitive to the effects of CaCl2 compared to ProPol
(Fig. 3D).
Processing of ORF1 cleavage site peptides by NoV Pro and ProPol
The processing order of NoV ORF1 has been well-established
with the Nterm/NTPase and NTPase/p20 ‘early’ sites being cleaved
ﬁrst. The remaining ‘late’ sites (p20/VPg, VPg/Pro, and Pro/Pol) are
not cleaved as efﬁciently (Hardy et al., 2002; Blakeney et al., 2003;
Belliot et al., 2003). However, there has been no determination of
the factors controlling the observed processing order. We hypothe-
sized that processing order is primarily controlled by the binding
afﬁnity and/or rate of reaction of NoV protease for each site. To test
this, we designed 14 amino acid (P7–P7′) FRET peptides represent-
ing each of the 5 ORF1 cleavage sites (Table 1). Peptides of this
length were used since a previous report demonstrated binding
efﬁciency was signiﬁcantly reduced for peptides less than 10
amino acids in length (Nakamura et al., 2005).
After 60 min under standard assay conditions using an enzyme:
substrate ratio of 1:15, both of the ‘early’ site peptides (Nterm/
NTPase, NTPase/p20) had reached 75% and 90% cleavage, respec-
tively, for Pro, and 80% and 100% cleavage, respectively, for ProPol
(Fig. 4A and B). In contrast, cleavage of the ‘late’ site Pro/Pol
peptide had reached only 15% and 30% completion by Pro and
ProPol respectively (Fig. 4A and B). The remaining two ‘late’
peptides, p20/VPg and VPg/Pro, did not reach more than 5%
cleavage after 1 h by either Pro or ProPol (Fig. 4A and B).
To determine if these reactions could be completed further, 20 h
incubations of the peptides were performed with an enzyme:
substrate ratio of 1:2 with Pro or ProPol (Fig. 4C). After 20 h of
incubation, the ‘early’ peptides displayed the same level of
cleavage observed previously. The Pro/Pol peptide reached 54%
cleavage with ProPol, but did not undergo further appreciable
cleavage by Pro, remaining at 17% cleavage after overnight incuba-
tion. The remaining ‘late’ peptides did undergo further cleavage
overnight by both Pro and ProPol resulting in 5–10% completion
(Fig. 4C). A previous study using synthetic substrates did not
observe any processing of the p20/VPg, VPg/Pro, or Pro/Pol
peptides by NoV Pro after an overnight incubation (Schefﬂer
et al., 2007).
Despite a fairly rapid initial rate of cleavage (especially for
ProPol), the Pro/Pol peptide did not show substantial additional
processing after approximately 45 min. Supplementation with
additional protease after 90 min of reaction resulted in only 6.8%
additional cleavage after a further 1.5 h of incubation (data not
Fig. 3. Effect of pH and buffering agent on NoV Pro and ProPol activity. NoV Pro data for panels A–C have been previously described (Viswanathan et al., 2013) and are
included for comparison. NoV Pro and ProPol concentrations were 0.5 mM and standard assay substrate was held at 100-fold excess for all conditions. Values were
determined at 60 min of reaction, and mean values for triplicate reactions are presented. Bars denote standard deviations. Data are presented as a percentage of the
maximum value in each panel. The maximum RLU observed for each panel (Pro, ProPol) were as follows: A, 2015, 1952; B, 1421, 1499; C, 1607, 1654; D, 974, 981. Panel A.
Effect of pH. Assays were conducted in 50 mM HEPES (pH6.8–8.0) and 50 mM Tris–HCl (pH8.0–9.0). Values for HEPES and Tris–HCl were normalized using pH8.0 data.
Panels B–D. Effects of various cations. Reactions were conducted in 10 mM HEPES, pH 7.6.
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sible for the observed cleavage inefﬁciency, as previously demon-
strated for some HCV protease reactions (Steinkuhler et al., 1998).
However, the addition of peptides representing both of the Pro/Pol
cleavage products, P7–P1 and P1′–P7′ (Table 1), to the reaction had
no effect on NoV protease activity on the Pro/Pol peptide when
added to the reaction assay at concentrations up to 500 mM (data
not shown).
Kinetic analysis of ORF1 peptides
The kinetic parameters for each peptide with NoV Pro and
ProPol are shown in Table 2, and a comparative summary of
overall enzymatic efﬁciency is displayed in Fig. 5. For both NoV Pro
and ProPol, the ‘early’ sites (Nterm/NTPase and NTPase/p20) were
cleaved with the highest velocities. Of the ‘late’ sites, only the Pro/
Pol peptide produced overall enzyme efﬁciency greater than
10 M−1 s−1 for both Pro and ProPol. All ORF1 ‘early’ site peptides,
along with the Pro/Pol ‘late’ peptide, displayed the same binding
afﬁnity (Km) for Pro and ProPol. The two remaining ‘late’ peptides,
p20/VPg and VPg/Pro, displayed a marked increase in Km with a
2–3-fold increase for Pro and a 2–4-fold increase for ProPol.
Enzyme turnover (kcat) for the peptides representing ORF1
cleavage sites varied by orders of magnitude (Table 2). For both
Pro and ProPol, the p20/VPg and VPg/Pro peptides showed 50–
200-fold lower enzyme turnover compared to ‘early’ sites. NoV
ProPol cleaved Nterm/NTPase more efﬁciently (kcat/Km) compared
to Pro. For the ‘late’ sites, Pro and ProPol cleaved the Pro/Pol site
with the highest efﬁciency but ProPol cleaved this site near 4-fold
more efﬁciently compared to Pro. The lowest processing efﬁcien-
cies observed for both enzymes were the p20/VPg and VPg/Pro
peptides. The VPg/Pro peptide was processed with 650 and320-fold lower efﬁciency compared to NTPase/p20 for NoV Pro
and ProPol respectively (Fig. 5). The p20/VPg peptide had over a
1000-fold decrease in efﬁciency for both Pro and ProPol compared
to NTPase/p20 (Fig. 5).
Protease activity on the two early site peptides was signiﬁ-
cantly greater than that observed for the standard peptide used for
the analysis of assay conditions (Fig. 3), reﬂected by 5–10-fold
increases in kcat/Km (Table 2). These differences were primarily due
to increases in kcat. It is surmised that these differences could be
due to the fact that the standard assay peptide is a GI NoV Nterm/
NTPase sequence (Zeitler et al., 2006). This peptide's amino acid
sequence (Table 1) was not observed to be present in any of the GII
NoV sequences in GenBank we examined. GI and GII Pro have been
reported to cleave this GI Nterm/NTPase peptide with similar
efﬁciencies (Chang et al., 2012; Viswanathan et al., 2013). Similarly,
we observed that GI Pro exhibits equivalent activity to GII pro on
the GII Nterm/NTPase peptide (Km 18.6 μM, kcat 12510–4 s−1, kcat/Km
675 M−1 s−1). This indicates that the noted differences in protease
activity between the GI and GII Nterm/NTPase peptides are likely to
be due to differences in their primary amino acid sequences.Competition of ‘early’ and ‘late’ peptides
In the polyprotein, all cleavage sites are conceivably present at
any given moment. To determine if peptides representing the
ORF1 cleavage sites could inﬂuence one another, a competition
experiment was designed. The enzyme turnover of the p20/VPg
peptide was over 300-fold slower compared to the NTPase/p20
peptide for NoV Pro (Table 2, Fig. 5). We hypothesized that the
p20/VPg peptide could act as a competitive inhibitor since it binds
the active site of the NoV proteases. A competition experiment
Fig. 4. ORF1 peptides are cleaved by both NoV Pro and ProPol. All assays were
conducted in triplicate at each point, using standard assay buffer and peptides
shown in Table 1. For panels A&B, 1 mM and 5 mM enzyme was used for ‘early’ and
‘late’ peptides respectively but enzyme:substrate ratio was the same for all
reactions (1:15). Panel A. Processing of ORF1 peptides by NoV Pro. Panel B.
Processing of ORF1 peptides by NoV ProPol. Panel C. 20 h incubation of Pro and
ProPol with ORF1 peptides using 1:2 enzyme:substrate (5 mM enzyme) ratio.
Asterisks (*) indicate a signiﬁcant difference (*po0.01) or (**po0.001) in percent
completion between Pro and ProPol for ORF1 peptides determined by two-way
ANOVA with Bonferroni's posttest. All statistical tests were performed using
GraphPad Prism™ Software. The maximum RLU observed were as follows: Panel
A: Nterm/NTPase, 2353, NTPase/p20, 2675, p20/Vpg, 240, Vpg/Pro, 278, Pro/Pol,
1705; Panel B: Nterm/NTPase, 3188, NTPase/p20, 2703, p20/Vpg, 298, Vpg/Pro, 728,
Pro/Pol, 3612; Panel C (Pro): Nterm/NTPase, 1860, NTPase/p20, 1655, p20/Vpg, 203,
Vpg/Pro, 202, Pro/Pol, 389; Panel C (ProPol): Nterm/NTPase, 1817, NTPase/p20,
1675, p20/Vpg, 144, Vpg/Pro, 246, Pro/Pol, 1098.
Fig. 5. Relative cleavage efﬁciencies of NoV ORF1 peptides by Pro and ProPol.
Amino acids surrounding scissile bond of ‘early’ and ‘late’ cleavage sites are shown.
Asterisk (*) denotes scissile bond at cleavage site. Fold change listed in kcat/Km for
NoV ORF1 peptides is relative to that observed for the most efﬁcient site (NTPase/
p20, shaded in black) for Pro and ProPol, respectively.
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peptide (substrate) over a range of concentration (Fig. 6). The ‘late’
p20/VPg peptide efﬁciently inhibited the cleavage of the ‘early’
peptide NTPase/p20 in a competitive manner with an inhibitor
constant, Ki, of 19.48 mM.Discussion
In this report, we provide evidence that human norovirus
(NoV) protease efﬁciency (kcat/Km) at each individual cleavage site
is the primary determinant controlling viral ORF1 polyprotein
processing order. Relative human NoV protease activity on pep-
tides representing all ﬁve ORF1 polyprotein cleavage sites was
correlated with the established processing order. Previous studies
have determined the human NoV ORF1 polyprotein cleavagepatterns, the di-amino acid cleavage sites, and the processing
order for the viral ORF1 polyprotein, although there is some minor
disagreement in the literature regarding cleavage order for some
of the late cleavage sites (Hardy et al., 2002; Blakeney et al., 2003;
Belliot et al., 2003; Schefﬂer et al., 2007). The fact that several,
long-lived, precursor proteins (e.g. ProPol) are observed during
in vitro self-cleavage reactions complicates the interpretation of
the ﬁnal cleavage kinetics (Belliot et al., 2003). The human NoV
protease cleavage sites have been grouped into two categories.
Two sites containing ‘Q–G’ at the cleavage point are cleaved
initially followed by cleavage at three sites containing ‘E–G/A’.
A previous report provided initial evidence for differential sensi-
tivity of NoV Pro and ProPol for peptides representing different
polyprotein cleavage sites, but did not provide a mechanistic
explanation for the observations (Schefﬂer et al., 2007).
In this report, we demonstrate that the rate of reaction (kcat) is
the apparent primary factor controlling NoV protease enzymatic
efﬁciency. Binding afﬁnity (Km) was not signiﬁcantly different for
the Nterm/NTPase, NTPase/p20, and Pro/Pol peptides for either
NoV Pro or ProPol. However, Km values for the two least efﬁciently
processed ‘late’ peptides (p20/VPg and VPg/Pro) had Km values
that were 2–4-fold higher, demonstrating an additional controlling
contribution from this parameter for some sites. The fact that the
p20/VPg peptide acted as a competitive inhibitor (Ki¼19.48 mM)
towards NoV Pro when mixed with the NTPase/p20 peptide may
indicate that the simultaneous presence of different cleavage sites
in the polyprotein may constitute another potential mechanism
for regulating protease activity during infection.
Previously, there has been no mechanistic explanation for the
observed human NoV polyprotein processing order. It is generally
surmised that viral polyprotein processing order could be con-
trolled by either the relative accessibility of protease cleavage sites
due to initial polyprotein conformation and changes in this
conformation following sequential protease cleavages or the
relative afﬁnity/activity of the protease for each cleavage sequence.
The conformation of the human NoV ORF1 polyprotein has been
previously suggested to inﬂuence proteolytic processing (Hardy
et al., 2002; Blakeney et al., 2003). However, another study
demonstrated that mutation of each of the individual human
NoV ORF1 polyprotein processing sites to inhibit protease cleavage
did not inhibit the ability of the viral protease to process the
remaining sites (Belliot et al., 2003). This indicated the NoV ORF1
Table 1
Peptides representing NoV ORF1 cleavage sites.
P7 P6 P5 P4 P3 P2 P1 P1′ P2′ P3′ P4′ P5′ P6′ P7′
Nterm/
NTPase
L G D Y E L Q * G P E D L A V
NTPase/p20 L D E F E L Q * G P A L T T F
p20/VPg S D D I K T E * G K K G K N K
VPg/Pro N E K L S F E * A P P S I W S
Pro/Pol E G E A T L E * G G D S K G T
Standard
assay
E P D F H L Q * G P E D L A K
The 14 amino acid FRET peptides (Dabacyl-14AA-Edans) used for kinetic studies are
listed. Amino acid numbering is from N-terminus to C-terminus as suggested by
Schechter and Berger (1967) Asterisks denote scissile bond. The sequence and
origin of the standard assay substrate was previously described (Zeitler et al., 2006;
Viswanathan et al., 2013).
n Cleavage site.
Table 2
Kinetics of NoV Pro and ProPol with ORF1 substrates.
Peptide Km (lM) kcat (110−4 s−1) kcat/Km (M−1 s−1)
NoV Pro cleavage efﬁciency
Nterm/NTPase 17.2871.99 109.274.04b 632b
NTPase/p20 17.8172.41 278.6712.26 1564
p20/VPg 62.4271.65a 0.9270.01 1.5
VPg/Pro 48.8972.97a 1.1870.21b 2.4b
Pro/Pol 18.0274.78 7.6170.66b 42b
Std. assay peptide 23.4774.84 34.172.48 145
NoV ProPol cleavage efﬁciency
Nterm/NTPase 16.4472.93 178.6710.99b 1086b
NTPase/p20 18.3071.71 251.577.67 1374
p20/VPg 77.93711.1a 0.9570.05 1.2
VPg/Pro 46.2478.00a 2.0070.01b 4.3b
Pro/Pol 14.0273.95 23.471.44b 167b
Std. assay peptide 22.6473.63 37.972.12 167
Peptides used in study are shown in Table 1. Reaction velocities used for non-linear
regression were the means of at least two independent experiments done in
triplicate.
a Km value was signiﬁcantly different from ‘early’ site Km values (po0.01) for
NoV Pro or ProPol by one-way ANOVA with Bonferroni's multiple comparisons test
(excluding standard assay peptide).
b Kinetic parameters were signiﬁcantly different between Pro and ProPol
(po0.01, two-tailed t test). All statistical tests were performed using GraphPad
Prism™ Software.
Fig. 6. p20/VPg peptide inhibits NoV Pro cleavage of NTPase/p20. Substrate–
velocity curves were generated with the independent variables [S] (NTPase/p20)
and [I] (p20/VPg). A global curve ﬁt was used to determine Ki for the p20/VPg
peptide using GraphPad Prism™ Software. Assays were conducted in standard
assay buffer and reaction velocity (average values from duplicate reactions) was
plotted over a range of substrate [S] and inhibitor [I] concentrations in mM. Data is
presented as a Lineweaver–Burk (double-reciprocal) plot.
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Similarly, in most cases, mutating individual poliovirus and hepatitis
C virus cleavage sites does not prevent cleavage at additional sites
(Cohen et al., 1996; Kolykhalov et al., 1994). Enzyme efﬁciency on
peptides representing the cleavage sites of the PV P2–P3 polyprotein
and HIV-1 Gag precursor have been shown to correlate with the
known processing order (Pallai et al., 1989; Billich et al., 1988; Darke
et al., 1988; Krausslich et al., 1989). Over 200-fold differences in
enzyme efﬁciency were observed between the 2B/2C and 3C/3D sites
for poliovirus (Pallai et al., 1989). In HIV, several hundred-fold
differences in efﬁciency were observed between p2/NC and CA/p2,
NC/p1 sites (Pettit et al., 1994; 2002). In the HIV Gag protein, only the
CA/p2 processing site has been demonstrated to be dependent on
cleavage at another site (Pettit et al., 1994).
The current studies indicate that the primary amino acid
sequence at each cleavage site is a controlling factor of NoV
protease enzyme efﬁciency. This has been shown for cleavage
sites of poliovirus and hepatitis C virus polyprotein processing
(Pallai et al., 1989; Kolykhalov et al., 1994; Landro et al., 1997;
Zhang et al., 1997; Steinkuhler et al., 1996). Changes of individual
amino acids surrounding the NoV Pro/Pol scissile bond have beenshown to affect protease activity (Belliot et al., 2003). However,
due to the structural differences between the peptides used in
these studies and the NoV polyprotein, the absolute enzyme
kinetics for processing the ORF1 polyprotein could differ if
structural elements outside of P7–P7′ are involved.
Previously, no direct comparisons of the activity of human NoV
Pro and ProPol with respect to assay buffer components have been
reported. Here, we demonstrate that human NoV ProPol has
essentially identical overall enzymatic activity and properties,
shares a similar pH sensitivity proﬁle, and is inhibited to nearly
the same extent by NaCl, KCl, MgCl2, MnCl2, and CaCl2 compared to
that previously described for NoV Pro (Viswanathan et al., 2013).
In addition, the current studies provide the ﬁrst measurements of
enzyme kinetics for ProPol.
We demonstrate that human NoV ProPol has equivalent, or
superior, activity to Pro for all ﬁve peptides representing the
human NoV ORF1 polyprotein cleavage sites. This data suggests
that ProPol may be the dominant viral protease in infected cells.
Both human NoV Pro and ProPol have been shown to be active
forms of the viral protease that process the viral ORF1 polyprotein
(Hardy et al., 2002; Blakeney et al., 2003; Belliot et al., 2003;
Schefﬂer et al., 2007). Differential roles of Pro and ProPol in ORF1
processing have been proposed (Belliot et al., 2003; Schefﬂer et al.,
2007), but the extent to which ProPol participates in the latter
stages of human NoV polyprotein processing is somewhat unclear.
In previous studies, human NoV ProPol has been shown to only
cleave the two ‘early’ sites (Hardy et al., 2002; Blakeney et al.,
2003; Belliot et al., 2003), and in one instance, the VPg/Pro ‘late’
site in trans (Schefﬂer et al., 2007). The feline calicivirus (FCV),
a vesivirus, and human sapoviruses do not produce mature Pro or
Pol in their lifecycles, but utilize ProPol for both polyprotein
processing and RNA replication (Sosnovtsev et al., 1999; Green,
2007). In human norovirus and murine norovirus, Pro/Pol is
cleaved more efﬁciently in mammalian cells than in vitro
(Sosnovtsev et al., 2006; Chang et al., 2006), but it remains unclear
the extent to which Pro and/or ProPol cleave the ORF1 polyprotein.
In murine norovirus (MNV), mature Pro has been shown to be
dispensable for ORF1 polyprotein processing in vivo by mutating
the Pro/Pol cleavage site and observing ORF1 proteolysis (Ward
et al., 2007). However, infectious virus was not recovered and the
mechanism of this inhibition was not determined as effects of the
mutation on viral replication were not clearly described. Although
apparently dispensable for intracellular viral polyprotein proces-
sing, mature viral protease and polymerase appear to be essential
J. May et al. / Virology 444 (2013) 218–224 223for successful NoV replication, but the precise roles for all three
enzymes in NoV replication require further investigation.Conclusion
We present in this communication a comprehensive compar-
ison of protease activities of GII human norovirus Pro and ProPol
with respect to various assay conditions and components. We
analyzed the enzymatic kinetics of Pro and ProPol using peptides
representing all ﬁve cleavage sites of the NoV ORF1 polyprotein to
provide an underlying mechanism for the established NoV poly-
protein processing order. Relative enzymatic efﬁciency (kcat/Km) at
each cleavage site was consistent with the previously established
polyprotein processing order, indicating that this is the primary
controlling factor. Differences in enzyme efﬁciency were primarily
due to differences in protein processing (kcat). Higher Km values at
the two most inefﬁciently processed sites were also observed.
Overall, ProPol demonstrated equivalent or superior cleavage
efﬁciency to Pro at all ORF1 cleavage sites, suggesting it may serve
as the dominant form of the viral protease, similar to that
observed for the vesiviruses and sapoviruses.Experimental procedures
Construction of the expression vectors
GII human NoV pro and propol were cloned from the cDNA clone
pGEMT-Easy-NV41 (provided by F. Parra, Universidad de Oviedo,
Spain), GenBank accession AJ583672.2. The construction of the Pro
expression vector was previously described (Viswanathan et al.,
2013). NoV propol was ampliﬁed using the forward primer NV3C-F
(5′-TGCATCACCATCACCATCACGCCCCACCAAGCATCTGGTC-3′) and the
reverse primer NVRp-R (5′-GCAGAATTCTCATTCGACGCCATCTT-
CATTCA-3′). The forward primer contained a hexahistidine tag along
with a 5′-TG di-nucleotide that formed a start codon after ligation
into the end-ﬁlled NdeI site in the pET-32a vector. The vector was
digested with NdeI, ﬁlled in with Pfu DNA polymerase to form a blunt
end, and subsequently digested with EcoRI. The cloned NoV propol
fragment was digested with EcoRI and ligated into the pET-32a vector.
The pET32NoVProPol construct was transformed into Escherichia coli
DH5α and selected for with 100 mg/ml ampicillin. Clones from
resistant colonies were sequenced to ensure successful insertion
and orientation.
To prevent self-cleavage of NoV ProPol during expression and
puriﬁcation, a Glu to Ala (E181A) mutation at the Pro/Pol cleavage
site that retains protease activity (Belliot et al., 2003) was
engineered using QuikChanges Lightning Site-directed Mutagen-
esis Kit (Stratagene). The forward and reverse primers used for this
mutagenesis were 5′-GAGGCTACACTTGCAGGTGGTGACAG-3′ and
5′-CTGTCACCACCTGCAAGTGTAGCCTC-3′ respectively.
NoV protease expression and puriﬁcation
Expression and puriﬁcation of NoV Pro and ProPol were per-
formed following previously described procedures (Viswanathan
et al., 2013; Yon et al., 2011). Brieﬂy, E. coli BL21 Star (DE3) cells were
transformed with pET32NoVPro. To prevent the accumulation of early
truncation products of ProPol observed in previous studies (Belliot
et al., 2003, 2005), E. coli Rosetta™ (DE3) pLysS cells were trans-
formed with pET32NoVProPol. Transformed cells were grown at 37 1C
in 750mL of Luria broth containing 100 mg/mL ampicillin and 34 mg/
mL chloramphenicol and transferred to fresh Luria broth containing
100 mg/mL ampicillin prior to induction. Protein expression was
induced with 0.25 mM IPTG for 18 h. Cells were harvested, lysed bysonication, centrifuged, and the supernatant incubated with Talon
metal afﬁnity resin (Clontech Laboratories, Inc.). The resin was then
washed with 10 mM imidazole, and the fusion protein was eluted
with 250mM imidazole. Eluted fractions were checked for purity by
SDS-PAGE and quantiﬁed spectrophotometrically. Fractions of highest
concentrations were pooled and dialyzed against storage buffer
(10 mM HEPES, pH 7.6, 50% glycerol, 10 mM DTT) (Fig. 1). Aliquots
were stored at −20 1C.
Norovirus protease assay
Protease assays to characterize Pro and ProPol were performed
as previously described (Viswanathan et al., 2013). Brieﬂy, the
standard assay peptide (Table 1), an Edans-Dabcyl 14 amino acid
FRET substrate (New England peptide, Inc.) was cleaved by active
NoV Pro or ProPol enzyme in 1X assay buffer (10 mM HEPES,
pH:7.6, 0.1% CHAPS, 10 mM DTT, 30% glycerol) and ﬂuorescence
was measured at excitation and emission maxima of 360 and
460 nm respectively in a SPECTRAmaxs GEMINI-EM Fluorescence
microplate reader (Molecular Devices, Inc.).
ORF1 peptide kinetic analysis
Peptides (Edans-Dabcyl, 14 amino acids) were custom synthe-
sized commercially by New England Peptide, Inc. The peptides
used were not ‘consensus’ sequences like the standard assay
substrate previously described (Hardy et al., 2002), but were
designed to match the most frequent, naturally-occurring, amino
acid sequences present in and around each of the ﬁve human NoV
ORF1 polyprotein cleavage sites of the GII NoV entries ﬁled in
GenBank (http://www.ncbi.nlm.nih.gov/genbank). Peptides were
designed by comparing 30 GII complete genome sequences. The
most common P7–P7′ sequence for each cleavage site was chosen
(ranging from 52% to 84% prevalence).
Kinetic analysis of human NoV Pro and ProPol using peptides
representing the human NoV ORF1 polyprotein cleavage sites
(Table 1) was performed in 1X assay buffer (Viswanathan et al.,
2013) (10 mM HEPES, pH:7.6, 0.1% CHAPS, 10 mM DTT, 30%
glycerol). For these experiments, 1.0 mM enzyme was used for
‘early’ sites. Both 1.0 mM and 5.0 mM enzyme was used for the ‘late’
site peptides to compensate for lower protease activity. Two-fold
serial dilutions of peptides ranging from 3.9 μM to 125 μM were
used for the Nterm/NTPase, NTPase/p20, and Pro/Pol peptides.
For the p20/VPg and VPg/Pro peptides, 50, 100, 150, and 200 mM
substrate was used to account for lower activity. Fluorescence
formed over a 30 min period of linear ﬂuorescence signal was
monitored at 1.0 min. intervals at 37 1C for efﬁcient peptides.
Fluorescence signal was monitored at 5.0 min intervals at 37 1C
for 75 min for the p20/VPg and VPg/Pro peptides to account for
slower kinetics. Background-subtracted ﬂuorescence (RFU) was
converted to products formed in micromolar concentration using a
standard curve of free Edans. Linear regression was used to
determine reaction velocities for each concentration of substrate.
Km and kcat were determined by non-linear regression analysis of
the μM product/time slope values using GraphPad PrismTM
Software.ORF1 peptide competition experiments
Substrate–velocity curves were generated in the presence of
various concentrations of the second (competitor) peptide.
For these studies, the NTPase/p20 peptide was designated as the
substrate, and the p20/VPg peptide was designated as the
‘inhibitor’ (I) or ‘competitor’. 1X assay buffer was used with
1.0 μM NoV Pro and two-fold serial dilutions of NTPase/p20
J. May et al. / Virology 444 (2013) 218–224224peptide ranging from 3.9 μM to 125 μM. A two-fold serial dilution
of p20/VPg peptide ranging from 15.6–125 μM was used for
competition. Background-subtracted, relative ﬂuorescence units
(RFU) from NTPase/p20 cleavage were converted into product
formed in micromolar concentration. Nonlinear regression global
curve ﬁt was used to determine Ki for the p20/VPg peptide using
GraphPad PrismTM Software.Acknowledgments
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